肿瘤内 Urelumab 联合 Nivolumab 治疗实体瘤患者的 I-II 期研究 (INTRUST)
2019年1月2日 更新者:Clinica Universidad de Navarra, Universidad de Navarra
开放标签、I-II 期研究,以评估肿瘤内 urelumab 联合全身性 nivolumab 在晚期实体瘤患者中的安全性和活性。
在研究期间将获得一系列肿瘤和血液样本,以表征肿瘤微环境中治疗引起的变化,以及反应的预测生物标志物。
研究概览
研究类型
介入性
注册 (预期的)
32
阶段
- 阶段2
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Jose L Perz Gracia, MD PhD
- 电话号码:+34948255400
- 邮箱:jlgracias@unav.es
研究联系人备份
- 姓名:Mercedes Egaña, MD PhD
学习地点
-
-
-
Madrid、西班牙、28022
- Clinica Universidad de Navarra
-
接触:
- Eduardo Castañón, MD PhD
-
-
Navarra
-
Pamplona、Navarra、西班牙、31008
- Clinica Universidad de Navarra
-
接触:
- Jose L Perez Gracia, MD PhD
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
纳入标准:
- 书面知情同意书。
- 患者必须愿意并能够遵守预定的就诊、治疗计划、实验室测试和研究的其他要求。
患者必须出现以下肿瘤类型:
- 对于 I 期部分,任何肿瘤类型的患者都有资格。
- 对于第二阶段,将建立两个队列:
我。队列 A 将包括呈现已知对程序性细胞死亡蛋白 1 (PD1)/程序性死亡配体 1 (PDL1) 阻断敏感的肿瘤类型的患者(例如:黑色素瘤、肾癌、肺癌、尿路上皮癌、结直肠癌呈现微卫星不稳定性(微星), …). 这些患者必须是天真的 PD1/PDL1 封锁。
二.队列 B 将包括在先前的 PD1/PDL1 阻断后进展的 PD1/PDL1 敏感肿瘤患者(例如:黑色素瘤、NSCLC、肾癌、膀胱癌……)。 在先前的 PD1/PDL1 阻断和纳入研究之间可能会进行额外的治疗,但如果在此之前立即进行,则必须在两种治疗之间观察至少 4 周的清除期。
- 根据研究者的标准,患者必须接受标准治疗,或者必须不符合标准治疗的条件。
- 患者必须出现至少一处肿瘤病变,可以进行序贯瘤内治疗和活检。
- 根据 RECIST 标准的可测量疾病。 可测量的病灶必须不同于肿瘤内 urelumab 治疗的病灶。
- 只要满足其他纳入标准,以前的治疗线就没有限制。
- 东部肿瘤合作组 (ECOG) 的表现状态为 0-1。
- 预期寿命 >12 周。
适当的器官功能定义为:
- 骨髓储备:白细胞(WBC):>=2000/mm3 中性粒细胞绝对计数(ANC)>=1500x 109/L;血小板计数 >=100000/ mm3 100 x 109/L;血红蛋白 >=9.0 克/分升)。
- 肝脏:胆红素 < 正常上限 (ULN) 的 1.5 倍,天冬氨酸转氨酶 (AST) 和丙氨酸转氨酶 (ALT) <3.0 x ULN(吉尔伯特综合征患者的 BR < 3 x ULN)。
- 肾脏:肌酐 <1.5 x ULN 或估计的肌酐清除率 > 40 ml/min,使用 Cokcroft-Gault 公式。
- 有生育能力的妇女(WOCBP,即:可生育、月经初潮后直到绝经后,除非永久不育)必须使用高效的方法来避免怀孕(即:雌激素和孕激素联合抑制排卵(口服、阴道内或经皮给药) );与抑制排卵相关的仅含孕激素的激素避孕药(口服、注射或植入);宫内节育器;宫内激素释放系统、双侧输卵管阻塞、切除输精管的伴侣或禁欲 23 周(30 天加上 nivolumab 所需的时间)和 urelumab 在最后一剂研究药物后经历五个半衰期)。
- WOCBP 必须在治疗开始前 24 小时内进行阴性血清或尿液妊娠试验(最低灵敏度 25 IU/L 或等效的 HCG 单位)。
- 与 WOCBP 性活跃的男性必须使用每年失败率低于 1% 的任何避孕方法。 接受 nivolumab 且与 WOCBP 性活跃的男性将被指示在最后一剂研究产品后坚持避孕 31 周。 没有生育能力的女性(即绝经后或手术绝育以及无精子症男性)不需要避孕。
- 患者必须年满 18 岁。
排除标准:
- 研究者认为可能会增加与研究参与或研究药物给药相关的风险、损害受试者接受计划治疗的能力或干扰研究结果解释的任何严重或不受控制的医学障碍。 应特别注意影响肝脏的情况。
- 患有活动性、已知或疑似自身免疫性疾病的受试者。 允许患有白斑病、I 型糖尿病、仅需要激素替代的自身免疫性疾病引起的残留甲状腺功能减退症、不需要全身治疗的牛皮癣或在没有外部触发的情况下预计不会复发的情况的受试者参加。
- 其他先前疗法(包括放射疗法)的治疗清除期将由研究人员确定,具体取决于相关毒性的解决方案。 有限野姑息性放疗不需要清除期。 如果 PD1/PDL1 阻断是先前的治疗,则必须在两种治疗之间观察至少 4 周的清除期。
- 如果患者的病症需要在研究药物给药后 14 天内使用皮质类固醇(> 10 mg 每日强的松当量)或其他免疫抑制药物进行全身治疗,则应将其排除在外。 在没有活动性自身免疫性疾病的情况下,允许吸入或局部使用类固醇和肾上腺替代剂量 > 10 mg/d 泼尼松当量
- 活动性脑转移可能会干扰结果的解释。 允许转移受控的受试者入组。 控制性脑转移将被定义为在放疗和/或手术治疗后至少 4 周内没有影像学进展。
- 孕妇或哺乳期患者。
- 已知的人类免疫缺陷病毒 (HIV) 检测阳性史或已知的获得性免疫缺陷综合症 (AIDS)。 不需要常规测试。
- 乙型肝炎病毒表面抗原 (HBV sAg) 或丙型肝炎病毒核糖核酸 (HCV RNA) 的阳性检测表明活动性或慢性感染。 丙型肝炎抗体呈阳性但聚合酶链式反应 (PCR) 定量丙型肝炎呈阴性的受试者符合条件。 已解决的甲型肝炎病毒感染史不是排除标准。
- 对研究药物成分过敏或对任何单克隆抗体有严重超敏反应史。
- 非自愿监禁或因治疗精神或身体(例如传染病)疾病而被强制拘留的囚犯或受试者。
- 根据研究者的意见,研究者认为可能会干扰研究结果的伴随或既往恶性肿瘤。
- 已知的药物或酒精滥用。
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:队列A
每 4 周将给予三剂瘤内 urelumab。
之后,Nivolumab 将在第 2 周期以 240 mg 的固定剂量给药,并在第 3 周期及以后以每 4 周 (Q4W) 的固定剂量 480 mg 给药
|
用肿瘤内 urelumab 治疗,然后给予 Nivolumab。
|
实验性的:队列B
每 4 周将给予三剂瘤内 urelumab。
之后,第 2 周期将以 240 mg 的固定剂量给予 Nivolumab,第 3 周期及以后将以 480 mg Q4W 的固定剂量给予
|
用肿瘤内 urelumab 治疗,然后给予 Nivolumab。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
不良事件数
大体时间:27个月
|
不良事件数
|
27个月
|
肿瘤内 urelumab 的推荐剂量
大体时间:12周
|
mg瘤内urelumab
|
12周
|
反应速度
大体时间:27个月
|
部分反应或完全反应的患者人数
|
27个月
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
总生存期(OS)。
大体时间:27个月
|
几个月到死
|
27个月
|
无进展生存期 (PFS)
大体时间:27个月
|
几个月直到进展
|
27个月
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6.
- Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL, Murphy KM. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008 Nov 14;322(5904):1097-100. doi: 10.1126/science.1164206.
- Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJ. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res. 2013 Oct 1;19(19):5381-9. doi: 10.1158/1078-0432.CCR-12-0781. Epub 2013 Jun 20.
- Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049.
- Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010 Oct 1;28(28):4324-32. doi: 10.1200/JCO.2010.28.9793. Epub 2010 Aug 9.
- Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother. 2005 Mar-Apr;28(2):129-35. doi: 10.1097/01.cji.0000154248.74383.5e.
- Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172.
- Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012 Mar 8;366(10):925-31. doi: 10.1056/NEJMoa1112824.
- Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. 2009 Apr 9;113(15):3546-52. doi: 10.1182/blood-2008-07-170274. Epub 2008 Oct 21.
- Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X, Sun M, Wen W, Dai X, Yang M, Lv Q, Lu B, Jiang J. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res. 2016 Mar 1;22(5):1173-1184. doi: 10.1158/1078-0432.CCR-15-1352.
- Melero I, Berman DM, Aznar MA, Korman AJ, Perez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015 Aug;15(8):457-72. doi: 10.1038/nrc3973.
- Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA, McCoy MJ, Robinson BW, Lake RA. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann Oncol. 2015 Dec;26(12):2483-90. doi: 10.1093/annonc/mdv387. Epub 2015 Sep 18.
- Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.
- Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015 Jul;15(7):409-25. doi: 10.1038/nrc3958. Erratum In: Nat Rev Cancer. 2015 Aug;15(8):509.
- Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006 Jun;67(6):1216-23. doi: 10.1016/j.urology.2005.12.014.
- Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, Kaufman HL, Andtbacka RH. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol. 2016 Aug 1;34(22):2619-26. doi: 10.1200/JCO.2016.67.1529. Epub 2016 Jun 13.
- Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015 Apr 3;348(6230):62-8. doi: 10.1126/science.aaa4967.
- Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007 Aug 15;179(4):2493-500. doi: 10.4049/jimmunol.179.4.2493.
- Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014 Feb;124(2):687-95. doi: 10.1172/JCI67313. Epub 2014 Jan 2.
- Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007 Sep;13(9):1050-9. doi: 10.1038/nm1622. Epub 2007 Aug 19.
- Golden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol. 2012 Aug 7;2:88. doi: 10.3389/fonc.2012.00088. eCollection 2012.
- Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72. doi: 10.1146/annurev-immunol-032712-100008. Epub 2012 Nov 12.
- Coley, W. B. Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and bacillus prodigiosus. Am J Med Sci. 131: 375-430, 1906
- Coley WB. The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. 1910;3(Surg Sect):1-48. No abstract available.
- Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today. 1992 Jan;13(1):11-6. doi: 10.1016/0167-5699(92)90198-G.
- Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat Immunol. 2007 Jan;8(1):11-3. doi: 10.1038/ni0107-11.
- Hammerich L, Binder A, Brody JD. In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf. Mol Oncol. 2015 Dec;9(10):1966-81. doi: 10.1016/j.molonc.2015.10.016. Epub 2015 Nov 10.
- Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014 Apr 1;20(7):1747-56. doi: 10.1158/1078-0432.CCR-13-2116.
- Kaminski JM, Shinohara E, Summers JB, Niermann KJ, Morimoto A, Brousal J. The controversial abscopal effect. Cancer Treat Rev. 2005 May;31(3):159-72. doi: 10.1016/j.ctrv.2005.03.004.
- Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1-22. doi: 10.1146/annurev-immunol-100311-102839. Epub 2011 Nov 17.
- Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012 Jul 13;12(8):557-69. doi: 10.1038/nri3254.
- Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, Pack M, Subklewe M, Sauter B, Sheff D, Albert M, Bhardwaj N, Mellman I, Steinman RM. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med. 1998 Dec 7;188(11):2163-73. doi: 10.1084/jem.188.11.2163.
- Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014 Nov 10;26(5):638-52. doi: 10.1016/j.ccell.2014.09.007. Epub 2014 Oct 16.
- Schraml BU, Reis e Sousa C. Defining dendritic cells. Curr Opin Immunol. 2015 Feb;32:13-20. doi: 10.1016/j.coi.2014.11.001. Epub 2014 Dec 3.
- Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, Keller AM, Joffre O, Zelenay S, Nye E, Le Moine A, Faure F, Donckier V, Sancho D, Cerundolo V, Bonnet D, Reis e Sousa C. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med. 2010 Jun 7;207(6):1261-71. doi: 10.1084/jem.20092618. Epub 2010 May 17.
- Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V, Vulink AJ, Hart DN, Radford KJ. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010 Jun 7;207(6):1247-60. doi: 10.1084/jem.20092140. Epub 2010 May 17.
- Zitvogel L, Kroemer G. CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance. Cancer Cell. 2014 Nov 10;26(5):591-3. doi: 10.1016/j.ccell.2014.10.008. Epub 2014 Nov 10.
- Martinez-Lopez M, Iborra S, Conde-Garrosa R, Sancho D. Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice. Eur J Immunol. 2015 Jan;45(1):119-29. doi: 10.1002/eji.201444651. Epub 2014 Nov 28.
- Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, Kroemer G, Martin F, Chauffert B, Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med. 2005 Oct 3;202(7):919-29. doi: 10.1084/jem.20050463. Epub 2005 Sep 26.
- Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A, Cho HI, Celis E, Lennox B, Knight SC, Padhya T, McCaffrey TV, McCaffrey JC, Antonia S, Fishman M, Ferris RL, Kagan VE, Gabrilovich DI. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010 Aug;16(8):880-6. doi: 10.1038/nm.2172. Epub 2010 Jul 11.
- Diaz-Valdes N, Manterola L, Belsue V, Riezu-Boj JI, Larrea E, Echeverria I, Llopiz D, Lopez-Sagaseta J, Lerat H, Pawlotsky JM, Prieto J, Lasarte JJ, Borras-Cuesta F, Sarobe P. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology. 2011 Jan;53(1):23-31. doi: 10.1002/hep.23980. Epub 2010 Dec 13.
- Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014 Nov 10;26(5):623-37. doi: 10.1016/j.ccell.2014.09.006. Epub 2014 Oct 16.
- Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J, Tung N, Chakarov S, Rivera C, Hogstad B, Bosenberg M, Hashimoto D, Gnjatic S, Bhardwaj N, Palucka AK, Brown BD, Brody J, Ginhoux F, Merad M. Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity. 2016 Apr 19;44(4):924-38. doi: 10.1016/j.immuni.2016.03.012.
- Sanchez-Paulete AR, Cueto FJ, Martinez-Lopez M, Labiano S, Morales-Kastresana A, Rodriguez-Ruiz ME, Jure-Kunkel M, Azpilikueta A, Aznar MA, Quetglas JI, Sancho D, Melero I. Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discov. 2016 Jan;6(1):71-9. doi: 10.1158/2159-8290.CD-15-0510. Epub 2015 Oct 22.
- Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remedios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tuting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Preville X, Uze G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, Andre F, Kroemer G, Zitvogel L. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26.
- Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough DF. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol. 2003 Oct;4(10):1009-15. doi: 10.1038/ni978. Epub 2003 Sep 21.
- Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, Gabriele L, Proietti E, Bracci L. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011 Feb 1;71(3):768-78. doi: 10.1158/0008-5472.CAN-10-2788. Epub 2010 Dec 13.
- Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011 Feb;30(1):16-34. doi: 10.3109/08830185.2010.529976.
- Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, Andre F, Tursz T, Kroemer G, Zitvogel L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007 Dec;220:47-59. doi: 10.1111/j.1600-065X.2007.00573.x.
- Lasarte JJ, Casares N, Gorraiz M, Hervas-Stubbs S, Arribillaga L, Mansilla C, Durantez M, Llopiz D, Sarobe P, Borras-Cuesta F, Prieto J, Leclerc C. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol. 2007 Jan 15;178(2):748-56. doi: 10.4049/jimmunol.178.2.748.
- Chicoine MR, Won EK, Zahner MC. Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse glioblastoma multiforme. Neurosurgery. 2001 Mar;48(3):607-14; discussion 614-5. doi: 10.1097/00006123-200103000-00032.
- Van De Voort TJ, Felder MA, Yang RK, Sondel PM, Rakhmilevich AL. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. J Immunother. 2013 Jan;36(1):29-40. doi: 10.1097/CJI.0b013e3182780f61.
- Weide B, Eigentler TK, Pflugfelder A, Zelba H, Martens A, Pawelec G, Giovannoni L, Ruffini PA, Elia G, Neri D, Gutzmer R, Becker JC, Garbe C. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. Cancer Immunol Res. 2014 Jul;2(7):668-78. doi: 10.1158/2326-6066.CIR-13-0206. Epub 2014 Apr 4.
- Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9237-42. doi: 10.1073/pnas.161293498. Epub 2001 Jul 24.
- Meng Y, Carpentier AF, Chen L, Boisserie G, Simon JM, Mazeron JJ, Delattre JY. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer. 2005 Oct 10;116(6):992-7. doi: 10.1002/ijc.21131.
- Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008 Dec 20;26(36):5896-903. doi: 10.1200/JCO.2007.15.6794. Epub 2008 Nov 24.
- Rehwinkel J, Reis e Sousa C. RIGorous detection: exposing virus through RNA sensing. Science. 2010 Jan 15;327(5963):284-6. doi: 10.1126/science.1185068.
- Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001 Oct 18;413(6857):732-8. doi: 10.1038/35099560.
- Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ, Restifo NP, Smyth MJ, Darcy PK, Kershaw MH. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother. 2011 May;60(5):671-83. doi: 10.1007/s00262-011-0984-8. Epub 2011 Feb 16.
- Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke U, Limmer A, Jonsson G, Holzel M, Tuting T. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 2014 Jun;4(6):674-87. doi: 10.1158/2159-8290.CD-13-0458. Epub 2014 Mar 3.
- Salazar AM, Erlich RB, Mark A, Bhardwaj N, Herberman RB. Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. Cancer Immunol Res. 2014 Aug;2(8):720-4. doi: 10.1158/2326-6066.CIR-14-0024. Epub 2014 May 6.
- Tormo D, Checinska A, Alonso-Curbelo D, Perez-Guijarro E, Canon E, Riveiro-Falkenbach E, Calvo TG, Larribere L, Megias D, Mulero F, Piris MA, Dash R, Barral PM, Rodriguez-Peralto JL, Ortiz-Romero P, Tuting T, Fisher PB, Soengas MS. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell. 2009 Aug 4;16(2):103-14. doi: 10.1016/j.ccr.2009.07.004.
- Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, Wang Y, Venzon D, Epstein SL, Segal DM. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol. 2011 Feb 15;186(4):2422-9. doi: 10.4049/jimmunol.1002845. Epub 2011 Jan 17.
- Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 1992 Jul 1;52(13):3528-33.
- Ahonen CL, Gibson SJ, Smith RM, Pederson LK, Lindh JM, Tomai MA, Vasilakos JP. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol. 1999 Oct 10;197(1):62-72. doi: 10.1006/cimm.1999.1555.
- Smyth EC, Flavin M, Pulitzer MP, Gardner GJ, Costantino PD, Chi DS, Bogatch K, Chapman PB, Wolchok JD, Schwartz GK, Carvajal RD. Treatment of locally recurrent mucosal melanoma with topical imiquimod. J Clin Oncol. 2011 Nov 20;29(33):e809-11. doi: 10.1200/JCO.2011.36.8829. Epub 2011 Oct 17. No abstract available.
- Redondo P, del Olmo J, Lopez-Diaz de Cerio A, Inoges S, Marquina M, Melero I, Bendandi M. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol. 2007 Jul;127(7):1673-80. doi: 10.1038/sj.jid.5700777. Epub 2007 Mar 22.
- Dewan MZ, Vanpouille-Box C, Kawashima N, DiNapoli S, Babb JS, Formenti SC, Adams S, Demaria S. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res. 2012 Dec 15;18(24):6668-78. doi: 10.1158/1078-0432.CCR-12-0984. Epub 2012 Oct 9.
- Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J, Novik Y, Tiersten A, Goldberg JD, Formenti SC, Bhardwaj N, Unutmaz D, Demaria S. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res. 2012 Dec 15;18(24):6748-57. doi: 10.1158/1078-0432.CCR-12-1149. Epub 2012 Jul 5.
- Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr, Gajewski TF. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19;11(7):1018-30. doi: 10.1016/j.celrep.2015.04.031. Epub 2015 May 7.
- Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Rohl I, Hopfner KP, Ludwig J, Hornung V. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature. 2013 Jun 20;498(7454):380-4. doi: 10.1038/nature12306. Epub 2013 May 30.
- Zhang X, Shi H, Wu J, Zhang X, Sun L, Chen C, Chen ZJ. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell. 2013 Jul 25;51(2):226-35. doi: 10.1016/j.molcel.2013.05.022. Epub 2013 Jun 6.
- Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity. 2014 Nov 20;41(5):843-52. doi: 10.1016/j.immuni.2014.10.019. Epub 2014 Nov 6.
- Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014 Nov 20;41(5):830-42. doi: 10.1016/j.immuni.2014.10.017. Epub 2014 Nov 5. Erratum In: Immunity. 2015 Jan 20;42(1):199.
- Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014 Aug;14(8):559-67. doi: 10.1038/nrc3770. Epub 2014 Jul 3.
- Prestwich RJ, Harrington KJ, Pandha HS, Vile RG, Melcher AA, Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther. 2008 Oct;8(10):1581-8. doi: 10.1586/14737140.8.10.1581.
- Smerdou C, Ochoa C, Quetglas JI, Fontanellas A, Gonzalez-Aseguinolaza G, Vile RG, Melero I. Immunology and gene therapy: shoulder to shoulder into the fray. Mol Ther. 2010 Mar;18(3):456-9. doi: 10.1038/mt.2010.7. No abstract available.
- Goins WF, Huang S, Cohen JB, Glorioso JC. Engineering HSV-1 vectors for gene therapy. Methods Mol Biol. 2014;1144:63-79. doi: 10.1007/978-1-4939-0428-0_5.
- Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D, Hwang TH. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70. doi: 10.1016/j.ymthe.2006.05.008.
- Rodriguez-Madoz JR, Prieto J, Smerdou C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther. 2005 Jul;12(1):153-63. doi: 10.1016/j.ymthe.2005.02.011.
- Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil JC, Olague C, Sola J, Sadaba B, Lacasa C, Melero I, Qian C, Prieto J. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol. 2004 Apr 15;22(8):1389-97. doi: 10.1200/JCO.2004.04.059.
- Agrawal N, Bettegowda C, Cheong I, Geschwind JF, Drake CG, Hipkiss EL, Tatsumi M, Dang LH, Diaz LA Jr, Pomper M, Abusedera M, Wahl RL, Kinzler KW, Zhou S, Huso DL, Vogelstein B. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15172-7. doi: 10.1073/pnas.0406242101. Epub 2004 Oct 7.
- Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V, Sangro B, Melero I, Qian C, Prieto J. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology. 2001 Jan;33(1):52-61. doi: 10.1053/jhep.2001.20796.
- Quetglas JI, Ruiz-Guillen M, Aranda A, Casales E, Bezunartea J, Smerdou C. Alphavirus vectors for cancer therapy. Virus Res. 2010 Nov;153(2):179-96. doi: 10.1016/j.virusres.2010.07.027. Epub 2010 Aug 6.
- Ott PA, Hodi FS. Talimogene Laherparepvec for the Treatment of Advanced Melanoma. Clin Cancer Res. 2016 Jul 1;22(13):3127-31. doi: 10.1158/1078-0432.CCR-15-2709. Epub 2016 May 4.
- Lorence RM, Reichard KW, Katubig BB, Reyes HM, Phuangsab A, Mitchell BR, Cascino CJ, Walter RJ, Peeples ME. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst. 1994 Aug 17;86(16):1228-33. doi: 10.1093/jnci/86.16.1228.
- Nistal-Villan E, Bunuales M, Poutou J, Gonzalez-Aparicio M, Bravo-Perez C, Quetglas JI, Carte B, Gonzalez-Aseguinolaza G, Prieto J, Larrea E, Hernandez-Alcoceba R. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model. Mol Cancer. 2015 Dec 16;14:210. doi: 10.1186/s12943-015-0479-x.
- Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095.
- Lundstrom K. Alphaviruses in gene therapy. Viruses. 2009 Jun;1(1):13-25. doi: 10.3390/v1010013. Epub 2009 Apr 21.
- Melero I, Quetglas JI, Reboredo M, Dubrot J, Rodriguez-Madoz JR, Mancheno U, Casales E, Riezu-Boj JI, Ruiz-Guillen M, Ochoa MC, Sanmamed MF, Thieblemont N, Smerdou C, Hervas-Stubbs S. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12. Cancer Res. 2015 Feb 1;75(3):497-507. doi: 10.1158/0008-5472.CAN-13-3356. Epub 2014 Dec 19.
- Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.
- Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C, Melero I, Prieto J. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol. 2000 Mar 15;164(6):3112-22. doi: 10.4049/jimmunol.164.6.3112.
- Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008 Jun;9(6):533-42. doi: 10.1016/S1470-2045(08)70107-4. Epub 2008 May 19. Erratum In: Lancet Oncol. 2008 Jul;9(7):613.
- Quetglas JI, Labiano S, Aznar MA, Bolanos E, Azpilikueta A, Rodriguez I, Casales E, Sanchez-Paulete AR, Segura V, Smerdou C, Melero I. Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade. Cancer Immunol Res. 2015 May;3(5):449-54. doi: 10.1158/2326-6066.CIR-14-0216. Epub 2015 Feb 17.
- Quetglas JI, Dubrot J, Bezunartea J, Sanmamed MF, Hervas-Stubbs S, Smerdou C, Melero I. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther. 2012 Sep;20(9):1664-75. doi: 10.1038/mt.2012.56. Epub 2012 Jun 26.
- John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL, Smyth MJ, Kershaw MH, Darcy PK. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res. 2012 Apr 1;72(7):1651-60. doi: 10.1158/0008-5472.CAN-11-2788. Epub 2012 Feb 7.
- Breitbach CJ, Moon A, Burke J, Hwang TH, Kirn DH. A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma. Methods Mol Biol. 2015;1317:343-57. doi: 10.1007/978-1-4939-2727-2_19.
- Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, Hwang TH, Burke JM, Bell JC, Kirn DH, Breitbach CJ. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther. 2015 Mar;23(3):602-8. doi: 10.1038/mt.2014.243. Epub 2014 Dec 22.
- Huang PI, Chang JF, Kirn DH, Liu TC. Targeted genetic and viral therapy for advanced head and neck cancers. Drug Discov Today. 2009 Jun;14(11-12):570-8. doi: 10.1016/j.drudis.2009.03.008. Epub 2009 Mar 17.
- Liu TC, Thorne SH, Kirn DH. Oncolytic adenoviruses for cancer gene therapy. Methods Mol Biol. 2008;433:243-58. doi: 10.1007/978-1-59745-237-3_15.
- Huarte E, Larrea E, Hernandez-Alcoceba R, Alfaro C, Murillo O, Arina A, Tirapu I, Azpilicueta A, Hervas-Stubbs S, Bortolanza S, Perez-Gracia JL, Civeira MP, Prieto J, Riezu-Boj JI, Melero I. Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. Mol Ther. 2006 Jul;14(1):129-38. doi: 10.1016/j.ymthe.2006.02.015. Epub 2006 Apr 19.
- Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011 May 27;34(5):637-50. doi: 10.1016/j.immuni.2011.05.006.
- Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol. 2008 Feb;20(1):17-22. doi: 10.1016/j.coi.2008.01.002. Epub 2008 Feb 12.
- Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN). Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016.
- Melief CJ. Selective activation of oxygen-deprived tumor-infiltrating lymphocytes through local intratumoral delivery of CD137 monoclonal antibodies. Cancer Discov. 2012 Jul;2(7):586-7. doi: 10.1158/2159-8290.CD-12-0229.
- Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011 Apr 15;17(8):2270-80. doi: 10.1158/1078-0432.CCR-10-2888. Epub 2011 Mar 9.
- Fransen MF, Cordfunke RA, Sluijter M, van Steenbergen MJ, Drijfhout JW, Ossendorp F, Hennink WE, Melief CJ. Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. Vaccine. 2014 Mar 26;32(15):1654-60. doi: 10.1016/j.vaccine.2014.01.056. Epub 2014 Feb 7.
- Marabelle A, Kohrt H, Levy R. New insights into the mechanism of action of immune checkpoint antibodies. Oncoimmunology. 2014 Aug 3;3(8):e954869. doi: 10.4161/21624011.2014.954869. eCollection 2014.
- Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013 Jun;123(6):2447-63. doi: 10.1172/JCI64859. Erratum In: J Clin Invest. 2013 Nov;123(11):4980.
- Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, Fahrni L, Schaller T, Freimoser-Grundschober A, Zielonka J, Stoma S, Rudin M, Klein C, Umana P, Gerdes C, Bacac M. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing. Clin Cancer Res. 2016 Sep 1;22(17):4417-27. doi: 10.1158/1078-0432.CCR-15-2622. Epub 2016 Apr 26.
- Palazon A, Martinez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Penuelas I, Hervas-Stubbs S, Rouzaut A, de Landazuri MO, Jure-Kunkel M, Aragones J, Melero I. The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov. 2012 Jul;2(7):608-23. doi: 10.1158/2159-8290.CD-11-0314. Epub 2012 Jun 19.
- Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013 Nov 15;19(22):6286-95. doi: 10.1158/1078-0432.CCR-13-1320. Epub 2013 Aug 27.
- Dubrot J, Milheiro F, Alfaro C, Palazon A, Martinez-Forero I, Perez-Gracia JL, Morales-Kastresana A, Romero-Trevejo JL, Ochoa MC, Hervas-Stubbs S, Prieto J, Jure-Kunkel M, Chen L, Melero I. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother. 2010 Aug;59(8):1223-33. doi: 10.1007/s00262-010-0846-9. Epub 2010 Mar 25.
- Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 1;25(7):876-83. doi: 10.1200/JCO.2006.08.3311.
- Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. Clin Cancer Res. 2016 Apr 15;22(8):1897-906. doi: 10.1158/1078-0432.CCR-15-1399.
- Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, Martin-Algarra S, Calvo A, Redrado M, Agliano A, Gonzalez A, Rodriguez I, Bolanos E, Hervas-Stubbs S, Perez-Calvo J, Benito A, Penuelas I, Vigil C, Richter J, Martinez-Forero I, Melero I. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol. 2011 Dec 1;187(11):6130-42. doi: 10.4049/jimmunol.1102209. Epub 2011 Nov 2.
- Bedrosian I, Mick R, Xu S, Nisenbaum H, Faries M, Zhang P, Cohen PA, Koski G, Czerniecki BJ. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol. 2003 Oct 15;21(20):3826-35. doi: 10.1200/JCO.2003.04.042.
- Gilliet M, Kleinhans M, Lantelme E, Schadendorf D, Burg G, Nestle FO. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood. 2003 Jul 1;102(1):36-42. doi: 10.1182/blood-2002-07-2274. Epub 2003 Jan 30.
- Melero I, Duarte M, Ruiz J, Sangro B, Galofre J, Mazzolini G, Bustos M, Qian C, Prieto J. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther. 1999 Oct;6(10):1779-84. doi: 10.1038/sj.gt.3301010.
- Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 1999 Aug 15;59(16):4035-41.
- Van Lint S, Renmans D, Broos K, Goethals L, Maenhout S, Benteyn D, Goyvaerts C, Du Four S, Van der Jeught K, Bialkowski L, Flamand V, Heirman C, Thielemans K, Breckpot K. Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells. Cancer Immunol Res. 2016 Feb;4(2):146-56. doi: 10.1158/2326-6066.CIR-15-0163. Epub 2015 Dec 11.
- Mazzolini G, Alfaro C, Sangro B, Feijoo E, Ruiz J, Benito A, Tirapu I, Arina A, Sola J, Herraiz M, Lucena F, Olague C, Subtil J, Quiroga J, Herrero I, Sadaba B, Bendandi M, Qian C, Prieto J, Melero I. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol. 2005 Feb 10;23(5):999-1010. doi: 10.1200/JCO.2005.00.463. Epub 2004 Dec 14.
- Alfaro C, Suarez N, Martinez-Forero I, Palazon A, Rouzaut A, Solano S, Feijoo E, Gurpide A, Bolanos E, Erro L, Dubrot J, Hervas-Stubbs S, Gonzalez A, Perez-Gracia JL, Melero I. Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation. PLoS One. 2011 Mar 14;6(3):e17922. doi: 10.1371/journal.pone.0017922.
- Melero I, Arina A, Murillo O, Dubrot J, Alfaro C, Perez-Gracia JL, Bendandi M, Hervas-Stubbs S. Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clin Cancer Res. 2006 Apr 15;12(8):2385-9. doi: 10.1158/1078-0432.CCR-06-0314. No abstract available.
- Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015 Jul 9;523(7559):231-5. doi: 10.1038/nature14404. Epub 2015 May 11.
- Melero I, Vile RG, Colombo MP. Feeding dendritic cells with tumor antigens: self-service buffet or a la carte? Gene Ther. 2000 Jul;7(14):1167-70. doi: 10.1038/sj.gt.3301234.
- Breton G, Lee J, Zhou YJ, Schreiber JJ, Keler T, Puhr S, Anandasabapathy N, Schlesinger S, Caskey M, Liu K, Nussenzweig MC. Circulating precursors of human CD1c+ and CD141+ dendritic cells. J Exp Med. 2015 Mar 9;212(3):401-13. doi: 10.1084/jem.20141441. Epub 2015 Feb 16.
- Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol. 2002 Jan;2(1):46-53. doi: 10.1038/nri704.
- Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99-146. doi: 10.1146/annurev.immunol.24.021605.090737.
- Maus MV, June CH. Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res. 2016 Apr 15;22(8):1875-84. doi: 10.1158/1078-0432.CCR-15-1433.
- Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014 May;4(5):522-6. doi: 10.1158/2159-8290.CD-13-0985.
- Arina A, Murillo O, Hervas-Stubbs S, Azpilikueta A, Dubrot J, Tirapu I, Huarte E, Alfaro C, Perez-Gracia JL, Gonzalez-Aseguinolaza G, Sarobe P, Lasarte JJ, Jamieson A, Prieto J, Raulet DH, Melero I. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma. Int J Cancer. 2007 Sep 15;121(6):1282-95. doi: 10.1002/ijc.22795.
- Kepp, O., L. Senovilla, I. Vitale, E. Vacchelli, S. Adjemian, P. Agostinis, L. Apetoh, F. Aranda, V. Barnaba, N. Bloy, L. Bracci, K. Breckpot, D. Brough, A. Buque, M. G. Castro, M. Cirone, M. I. Colombo, I. Cremer, S. Demaria, L. Dini, A. G. Eliopoulos, A. Faggioni, S. C. Formenti, J. Fucikova, L. Gabriele, U. S. Gaipl, J. Galon, A. Garg, F. Ghiringhelli, N. A. Giese, Z. S. Guo, A. Hemminki, M. Herrmann, J. W. Hodge, S. Holdenrieder, J. Honeychurch, H. M. Hu, X. Huang, T. M. Illidge, K. Kono, M. Korbelik, D. V. Krysko, S. Loi, P. R. Lowenstein, E. Lugli, Y. Ma, F. Madeo, A. A. Manfredi, I. Martins, D. Mavilio, L. Menger, N. Merendino, M. Michaud, G. Mignot, K. L. Mossman, G. Multhoff, R. Oehler, F. Palombo, T. Panaretakis, J. Pol, E. Proietti, J. E. Ricci, C. Riganti, P. Rovere-Querini, A. Rubartelli, A. Sistigu, M. J. Smyth, J. Sonnemann, R. Spisek, J. Stagg, A. Q. Sukkurwala, E. Tartour, A. Thorburn, S. H. Thorne, P. Vandenabeele, F. Velotti, S. T. Workenhe, H. Yang, W. X. Zong, L. Zitvogel, G. Kroemer, and L. Galluzzi. 2014. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3: e955691
- Antoniades J, Brady LW, Lightfoot DA. Lymphangiographic demonstration of the abscopal effect in patients with malignant lymphomas. Int J Radiat Oncol Biol Phys. 1977 Jan-Feb;2(1-2):141-7. doi: 10.1016/0360-3016(77)90020-7. No abstract available.
- Ruocco MG, Pilones KA, Kawashima N, Cammer M, Huang J, Babb JS, Liu M, Formenti SC, Dustin ML, Demaria S. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest. 2012 Oct;122(10):3718-30. doi: 10.1172/JCI61931. Epub 2012 Sep 4.
- Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, Camerlingo R, Capone M, Madonna G, Festino L, Caraco C, Di Monta G, Marone U, Di Marzo M, Grimaldi AM, Mori S, Ciliberto G, Ascierto PA. Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. Oncoimmunology. 2015 May 22;4(6):e1008842. doi: 10.1080/2162402X.2015.1008842. eCollection 2015 Jun.
- Korangy, F., M. ElGindi, D. Pratt, D. Venzon, A. Duffy, O. Makarova-Rusher, S. Kerkar, D. Kleiner, B. Wood, and T. Greten. 2016. Tremelimimab activates CD4 and CD8+T cells in patients with hepatocellular carcinoma. Cancer immunology research 4
- Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, Freyburger L, Clement O, Marcheteau E, Gey A, Fraisse G, Bouguin C, Merillon N, Dransart E, Tran T, Quintin-Colonna F, Autret G, Thiebaud M, Suleman M, Riffault S, Wu TC, Launay O, Danel C, Taieb J, Richardson J, Zitvogel L, Fridman WH, Johannes L, Tartour E. Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med. 2013 Feb 13;5(172):172ra20. doi: 10.1126/scitranslmed.3004888. Erratum In: Sci Transl Med. 2013 Mar 27;5(178):178er2. Suleman, Muhammed [corrected to Suleman, Muhammad].
- Mikhak Z, Strassner JP, Luster AD. Lung dendritic cells imprint T cell lung homing and promote lung immunity through the chemokine receptor CCR4. J Exp Med. 2013 Aug 26;210(9):1855-69. doi: 10.1084/jem.20130091. Epub 2013 Aug 19.
- Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M, Senzer NN. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer. 2016 Mar 15;4:12. doi: 10.1186/s40425-016-0116-2. eCollection 2016.
- Berraondo P, Ochoa MC, Rodriguez-Ruiz ME, Minute L, Lasarte JJ, Melero I. Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop. Cancer Res. 2016 May 15;76(10):2863-7. doi: 10.1158/0008-5472.CAN-15-3279. Epub 2016 May 2.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (预期的)
2019年1月30日
初级完成 (预期的)
2023年1月30日
研究完成 (预期的)
2023年1月30日
研究注册日期
首次提交
2018年12月20日
首先提交符合 QC 标准的
2019年1月2日
首次发布 (实际的)
2019年1月3日
研究记录更新
最后更新发布 (实际的)
2019年1月3日
上次提交的符合 QC 标准的更新
2019年1月2日
最后验证
2018年11月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Urelumab + 纳武单抗的临床试验
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb主动,不招人
-
Bristol-Myers Squibb完全的癌症 - 实体瘤和 B 细胞非霍奇金淋巴瘤美国, 法国, 西班牙, 德国
-
Jason J. Luke, MDArray BioPharma主动,不招人
-
Parker Institute for Cancer ImmunotherapyBristol-Myers Squibb; Cancer Research Institute, New York City完全的
-
Amgen招聘中黑色素瘤意大利, 西班牙, 南非, 日本, 塞尔维亚, 波斯尼亚和黑塞哥维那, 美国, 阿根廷, 智利, 乔治亚州, 马来西亚, 大韩民国, 法国, 德国, 荷兰, 克罗地亚, 泰国, 巴西, 台湾, 罗马尼亚, 墨西哥, 印度
-
Ikena OncologyBristol-Myers Squibb完全的肿瘤 | 肿瘤转移 | 实体瘤 | 转移癌 | 膀胱癌 | 晚期实体瘤 | 晚期癌症 | 膀胱尿路上皮癌 | 尿路上皮癌 | 转移性尿路上皮癌 | 实体瘤,成人 | 膀胱疾病 | 实体癌 | 恶性肿瘤 | 肿瘤,膀胱 | 局部晚期实体瘤 | 膀胱尿路上皮癌 | 膀胱肿瘤 | 转移性膀胱癌 | 尿路上皮肿瘤 | 肿瘤,膀胱美国
-
Gustave Roussy, Cancer Campus, Grand Paris招聘中复发/难治性 ALK+ 间变性大细胞淋巴瘤法国, 丹麦, 荷兰
-
Famewave Ltd.Bristol-Myers Squibb主动,不招人